Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Continuous manufacturing is a process in which input materials are continuously fed and converted, and processed output materials are continuously removed from the system. Characteristics are the products in one process that form the direct base material for the next process. Pharmaceutical Continuous Manufacturing (PCM) facilitates improved drug quality and control, shorter development time, lower costs, and a more flexible supply chain. While batch processes to produce tablets (intermittent steps to produce drug products, often at many different sites) are an important pillar of solid dosage production today, it is expected that more solid dosage drugs will be produced using continuous manufacturing methods. PCM equipment manufacturer allows for Continuous Manufacturing of pharmaceutical solids from powder to coated tablet via direct compression, dry and wet granulation.

Market Overview:

The latest research study on the global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market finds that the global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market reached a value of USD 1263.62 million in 2023. It’s expected that the market will achieve USD 2393.39 million by 2029, exhibiting a CAGR of 11.23% during the forecast period.

KORSCH ACQUIRES MEDELPHARM TO STRENGTHEN R&D PRODUCT LINE

February 1, 2023
Innovative compaction simulator technology adds early-stage material characterization and scale-up capability to the KORSCH R&D product portfolio.

KORSCH AG, the global leader in tablet press technology, offering solutions for product development, scale-up, high-speed production, multi-layer, continuous manufacturing, and high-containment applications – has announced the acquisition of MEDELPHARM, the innovator and global leader in compaction simulator technology.

After working closely for more than a year in the context of a global strategic partnership, the acquisition leverages the companies’ combined 135-plus years of experience with small-scale, fully instrumented tablet compression equipment. The KORSCH R&D product portfolio addresses and overcomes longstanding challenges, from early-stage powder characterization and formulation development, to predictive scale-up and production support. 

Benefits of pharmaceutical continuous manufacturing

Continuous production has become the norm in petrochemicals, steel, food and beverage, and other industries. As manufacturing technologies in the pharmaceutical industry mature and the cost of sensor and analytical technologies declines, regulatory agencies and the economic environment encourage drug and pharmaceutical device manufacturers to pursue innovation and consider more efficient continuous manufacturing processes. Continuous manufacturing of pharmaceutical products uses the same equipment during development, clinical sample reagents, and commercial production phases, and adjusts batch sizes based on changes in run time. This means shorter development times and lower regulatory risks, accelerating the transition from development to commercial scale. Findings from an FDA survey indicate that PCM-based programs can achieve faster time to market and regulatory approval compared to traditional bulk submissions. Continuous manufacturing eliminates intervals and pauses between batch production process steps, reduces the chance of defects and errors, helps shorten the production cycle, improves drug quality and production efficiency to a certain extent, and has the characteristics of agility and flexibility. Continuous manufacturing can provide significant cost savings. Production facilities can run machines continuously 24/7 until input materials are exhausted or an order is completed. This means manufacturers can more easily achieve economies of scale and achieve lower production costs, resulting in lower drug prices for patients. Through lower personnel requirements and an increase in high-tech jobs with less manual processing, the country's manufacturing industry can be revitalized and supply chain security improved. Continuous manufacturing has a lower environmental impact. For example, less solvent is used, and energy costs are lower; less waste; less handling and contact with materials, and easier cleaning. Overall, the advantages of continuous pharmaceutical manufacturing include smaller equipment footprints, fewer process steps, optimized process control, faster manufacturing, cost reduction, and mitigation of drug shortages and recalls.

Global drug shortage

According to the American Society of Health-System Pharmacists (ASHP), there are more than 300 shortage advisories for drugs, biologics, devices, and specific dosage forms. According to ASHP, the top five critical shortages by drug category are antimicrobials, chemotherapy drugs, central nervous system drugs, fluids/electrolytes, and hormones. According to the FDA's database of current and resolved drug shortages and discontinuation reports, 140 drugs are currently experiencing shortages, and 241 certain drugs are permanently discontinued, of which 41 shortages have been resolved. Medicine shortages in Europe have been increasing for more than 20 years. In 2023, a combination of factors such as increased demand (especially for critical drugs), economic inflation, and international geopolitical instability will cause the European pharmaceutical supply chain to be severely affected. According to the list of shortage drugs released by China from 2018 to 2021 (a total of 408 types of drugs), the most serious shortage is injections, accounting for 45.3% (185/408). From the perspective of therapeutic characteristics, almost all categories of drugs are in shortage, of which cardiovascular drugs, nervous system drugs, anti-tumor and immunomodulatory drugs, and blood and hematopoietic organ drugs account for more than 10%.

Rising wealth and population growth in developing countries, due to aging populations and rising chronic diseases in developed countries, are creating high demand for the global pharmaceutical industry. Pharmaceutical manufacturing challenges are diverse, including insufficient productivity, labor shortages, speed of product inspection, natural disasters, and the speed of adopting new technologies. The OECD found that 60% of global shortages are due to manufacturing and quality issues, including material shortages and production suspensions due to quality issues and technical problems. The COVID-19 pandemic has made it even more apparent that manual checks on product quality must be reduced, for example by eliminating processes such as hand-picking products for testing. Global drug shortages highlight the need for improved supply chain management and stronger regulation, requiring the pharmaceutical industry and governments to work together to develop effective solutions.

Region Overview:

In 2022, the share of the Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market in North America stood at 36.82%.

Company Overview:

The major players operating in the Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market include GEA, Syntegon, IMA Group, Glatt GroupFette Compacting GmbH, etc. Among which, GEA ranked top in terms of sales and revenue in 2023.

GEA is one of the world’s largest systems suppliers for the food, beverage and pharmaceutical sectors. GEA's portfolio includes machinery and plants as well as advanced process technology, components and comprehensive services. Used across diverse industries, they enhance the sustainability and efficiency of production processes globally.

GEA's business model has evolved significantly since GEA's founding in 1881 as a metals trading company. Today, GEA's five business divisions are supported by more than 18,000 dedicated employees located in 62 countries. GEA customers benefit from GEA's global reach, extensive local presence, and from depth and breadth of processing knowledge and portfolio, underpinned by a strong sense of purpose and responsibility.

GEA is proud to serve customers around the world in the food, beverage, chemical, pharma, dairy processing, dairy farming and marine industries. Many of these sectors are experiencing tremendous growth given global trends and other socio-economic drivers – contributing to GEA’s solid performance. GEA's strategy for the next five years, Mission 26, is based on strengthening GEA's position in these key industries while focusing on defined levers to accelerate profitable growth and better serve our customers.

GEA has developed a tailored pathway to become a sustainability leader in the industry, with clear KPIs that focus on delivering sustainable solutions, ensuring responsible operations, and becoming an employer of choice by 2026. GEA places great expectations on the growth opportunities offered by innovation and digitalization. In the coming five years, GEA plans to significantly increase our R&D spending to accelerate the development of new products. As a result, their share of GEA sales is expected to grow substantially. Driven by changing consumer expectations, the New Food market is growing rapidly. New Food will be a key lever in helping GEA make Mission 26 a success. Substantial growth opportunities for GEA also lie in sales. GEA's goal is to grow sales of new machines by 4.0 to 5.0 percent per year by 2026. Measures include analyzing in detail at the business unit level in which regions GEA has the greatest growth opportunities and how can optimize route-to-market. Service is a resilient and profitable business for GEA. GEA's aim for 2026 is to increase service coverage and expand GEA's service business with customers, thereby boosting recurring revenue streams. For example, GEA is looking to make the shift from an incident-driven to a subscription-based business model. This overall approach is expected to generate annual organic revenue growth of 5.0 to 6.0 percent by 2026.

Segmentation Overview:

By type, Wet Granulation System segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Pharmaceutical Companies segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market covered in Chapter 3:

L.B. Bohle
Fette Compacting GmbH
Syntegon
IMA Group
GEA
Freund Corporation
Glatt Group

In Chapter 4 and Chapter 14.2, on the basis of types, the Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market from 2019 to 2030 is primarily split into:

Wet Granulation System
Continuous Direct Compression (CDC) System

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage market from 2019 to 2030 covers:

Pharmaceutical Companies
CMO/CDMO

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)